Agreement for the Examination of Cooperation with Wize Pharma; Immaterial Relations with an independent Director

Tel Aviv (June 12, 2018) – On June 11, 2018, Diagnostear Ltd. (“Diagnostear“)[1] entered into an agreement (the “Agreement”) with Wize Pharma Ltd. (“Wize Pharma” and together with Diagnostear  the “Parties“) to examine cooperation between the Parties for the development of a companion diagnostic tool of responders and non-responders to Wizes Pharma’s dry eye drug for patients suffering from Sjögren’s syndrome (the “Drug”). To the Company’s best knowledge, Wize Pharma is in the course of an advanced clinical trial in a medical institution in Israel for said drug (the “Clinical Trial“).

[1] The Company holds approximately 88% of the issued and paid share capital of Diagnostear, through XL Vision Sciences Ltd., a wholly owned company.

Link to the complete article

Link to Newsroom

Comments are closed